Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
A Phase II, double-blind, randomized, placebo-controlled ascending dose titration study to
evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of multiple
ascending doses of CK-2017357 to an individual patient maximum tolerated dose (MTD), using a
within-patient twice daily (BID) dose-titration regimen in ALS patients on 50 mg riluzole
once daily (QD).